chevron_left Categories

Other related webinars

Are Genes Patentable in the United States? (A Re...

Friday, 26th August, 2011
Time : 02:00 PM | 11:00 AM

GLP Regulations – A Simplified Overview for Ac...

Friday, 2nd December, 2011
Time : 02:00 PM | 11:00 AM

Understanding FDA Guidance on GLP for Nonclinica...

Thursday, 22nd December, 2011
Time : 02:00 PM EST | 11:00 AM PST

FDA and EMA successful development and approvals...

Friday, 22nd June, 2012
Time : 02:00 PM EST | 11:00 AM PST

Strategic insights into European (CHMP/EMA) and ...

Monday, 3rd December, 2012
Time : 02:00 PM EST | 11:00 AM PST

FDA Approvals and Insights: Understanding US-FDA...

Friday, 1st March, 2013
Time : 02:00 PM IST | 09:30 AM CET

Effective Responses to FDA Warning Letters on Qu...

Friday, 15th August, 2014
Time : 01:00 PM | 10:00 AM

FDA’s view of Purchasing Controls, regulatory ...

Friday, 3rd October, 2014
Time : 01:00 PM EST | 10:00 AM PST

A review of the FDA’s oversight, regulatory re...

Friday, 16th January, 2015
Time : 01:00 PM EST | 10:00 AM PST

Preparing for and Managing EU Notified Bodies Au...

Thursday, 28th January, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Biopharmaceutical Method Transfer – Using a Qu...

Friday, 20th May, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Quality systems for Analytical Instrumentation a...

Friday, 24th June, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Effective Investigation of Deviations & Putting ...

Friday, 2nd September, 2016
Time : 04:00 PM IST | 11:30 AM BST

NO More Written Procedure (Standard Operating Pr...

Friday, 14th October, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Best Practices in Supplier Management: Evaluatio...

Friday, 20th January, 2017
Time : 10:00 AM EST | 04:00 PM BST

Using Quality Indicators for Successful FDA QSR ...

Friday, 10th February, 2017
Time : 04:00 PM IST | 11:30 AM BST

Effective Management Reviews for FDA and Managem...

Friday, 21st April, 2017
Time : 01:00 PM EDT | 10:00 AM PDT

FDA Internal Audits - An Important Tool for Avoi...

Friday, 30th June, 2017
Time : 04:00 PM IST | 11:30 AM BST

FDA Regulatory Rules for Supply Chain and Manufa...

Friday, 4th August, 2017
Time : 11:00 AM EDT | 08:00 AM PDT

FDA - Training Modules

Friday, 28th September, 2018
Time : Set the Time | Set the Time

FDA Quality Systems Inspection Technique (QSIT) ...

Friday, 26th October, 2018
Time : 01:00 PM EDT | 10:00 AM PST

Key Element of Quality Management System Complia...

Friday, 30th August, 2019
Time : 04:00 PM IST | 11:30 AM BST

A CAPA Primer - Elements of a CAPA Program

Friday, 28th February, 2020
Time : 01:00 PM EST | 10:00 AM PST

How To Respond To FDA 483s

Wednesday, 2nd March, 2022
Time : 01:00 PM EST | 10:00 AM PST

FDA Expectations from Supplier Management for GM...

Friday, 22nd April, 2022
Time : 01:00 PM EDT | 10:00 AM PDT

The clinical, regulatory and business challenges...

Friday, 19th August, 2022
Time : 01:00 PM EST | 10:30 AM PST

The FDA CGMP and Data Integrity in Pharmaceutica...

Friday, 7th April, 2023
Time : 01:00 PM EST | 10:30 AM PST

FDA PMA Submissions - Contents, Process, Pitfall...

Friday, 21st April, 2023
Time : 01:00 PM IST | 10:00 AM PST

Complaint Handling in Compliance with FDA and IS...

Friday, 26th May, 2023
Time : 01:00 PM EST | 10:00 AM PST

Recorded Webinar

Effective Responses to FDA Warning Letters on Quality Systems

timelapse 60 mins with 10-15 mins of Q and A

Note:

This webinar occured in the past
Along with recorded webinar, copy of presentation slides will be shared
Recorded Webinar can be played unlimited times

Speaker/Presenter

Short Abstract

FDA has increasingly turned to Warning Letters as a tool for voluntary compliance. Unfortunately the types of issues FDA is including in Warning Letters makes mere compliance not sufficient, but rather state of the art quality systems. It is no longer sufficient to have a procedure and follow it. FDA may consider the procedure inadequate and evidence you follow the procedure may not be acceptable to FDA as you may have not done it up to the FDA requirements.

In this webinar we will discuss the kinds of issues FDA is citing in Warning Letters relating to quality system deficiencies. We will discuss inadequate responses and the FDA consequences for such. We will discuss how to prepare a response FDA will consider acceptable.

Finally we will discuss how to establish quality systems that will be acceptable to FDA and avoid Warning Letters.

Your instructor has held almost every field position within FDA during his 18 year career with FDA, Investigator, Supervisory Investigator, Compliance Officer, Director of Import Operations, Acting Director of Compliance and Acting District Director. He also has over 18 years experience in the Medical Device industry rising from an RA Manager to being a Vice President of RA/QA/Clinical for major class 3 device manufacturers.

Course Objectives:

  • Become familiar with issues that are in FDA Warning Letters
  • Know what kinds of response will not be acceptable to FDA
  • Know how to effective respond to a Warning Letter
  • Know what kinds of company actions can avoid Warning Letters
  • Know how to negotiate with FDA to effectively close Warning Letters


Apply for this webinar

Who should attend

VP’s, Directors, and Managers of Regulatory Affairs, Quality Assurance. Internal GMP Auditors, Consultants who assist firms with Warning Letter remediation.

Content Disclaimer

Contents in our website are from external websites. Links to and content from external website are provided for the convenience of users. Biopractice.com takes no responsibility for the content of such links and websites.

//